Startup profile · funding coverage
Sling Therapeutics funding, valuation and investors
Clinical-stage biotech developing oral linsitinib for thyroid eye disease; closed a $123 million Series C.
Keep track of Sling Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$123M · September 16, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$123M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Ann Arbor, Michigan, USA
Investors in latest funding
Lead: Forbion
Other: TPG Life Sciences Innovations , Sectoral Asset Management
Overview
Sling Therapeutics is developing linsitinib, an oral small-molecule IGF-1R inhibitor for thyroid eye disease. On September 16, 2026 Sling announced a $123 million Series C led by Forbion, with participation from TPG Life Sciences Innovations and Sectoral Asset Management.
Why Sling Therapeutics is interesting
Sling has a low-difficulty brand query and a late-stage Phase 3 asset, making its funding record useful even if the absolute search volume is modest.
Product & use cases
Oral small-molecule therapy development for thyroid eye disease.
Key facts
- Sep 16, 2026: $123M Series C
- Forbion led the round
- Capital supports the Phase 3 ORBIT program
Funding history (newest first)
Series C
2026-09-16 $123M- Forbion (lead)
- TPG Life Sciences Innovations (participant)
- Sectoral Asset Management (participant)
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Sling Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.